Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

SEC Filings

Form 8-K
PACIRA PHARMACEUTICALS, INC. filed this Form 8-K on 03/13/2017
Document Outline
Entire Document (916 KB)
Subdocument 1 - 8-K - 8-K
Page 1 - UNITED STATES
Page 2 - Item 1.01.
Page 3 - Item 2.03.
Page 4 - Item 9.01.
Page 5 - SIGNATURES
Page 6 - EXHIBIT INDEX
Subdocument 2 - EX-4.1 - EX-4.1
Page 1 - Exhibit 4.1
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - Company
Page 7 - Bid Solicitation Agent
Page 8 - Conversion Agent
Page 9 - Daily VWAP
Page 10 - Ex-Dividend Date
Page 11 - Majority Ownership Exception
Page 12 - Interest Payment Date
Page 13 - Observation Period
Page 14 - Paying Agent
Page 15 - Relevant Exchange
Page 16 - Subsidiary
Page 17 - Trustee
Page 18 - Form of Notes.
Page 19 - N/A
Page 20 - Execution, Authentication and Delivery of Notes.
Page 21 - Note Registrar
Page 22 - Restricted Securities
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - Mutilated, Destroyed, Lost or Stolen Notes.
Page 27 - Temporary Notes.
Page 28 - Cancellation of Notes Paid, Converted, Etc.
Page 29 - Satisfaction and Discharge.
Page 30 - Paying Agent
Page 31 - provided
Page 32 - N/A
Page 33 - Stay, Extension and Usury Laws.
Page 34 - Further Instruments and Acts.
Page 35 - Acceleration; Rescission and Annulment
Page 36 - Additional Interest in Lieu of Reporting Default
Page 37 - Payments of Notes on Default; Suit Therefor.
Page 38 - N/A
Page 39 - Application of Monies Collected by Trustee.
Page 40 - Proceedings by Trustee.
Page 41 - Direction of Proceedings and Waiver of Defaults by Majority of Holders.
Page 42 - provided
Page 43 - Reliance on Documents, Opinions, Etc.
Page 44 - N/A
Page 45 - No Responsibility for Recitals, Etc.
Page 46 - Compensation and Expenses of Trustee.
Page 47 - provided, however
Page 48 - Acceptance by Successor Trustee.
Page 49 - Succession by Merger, Etc.
Page 50 - Action by Holders.
Page 51 - Company-Owned Notes Disregarded.
Page 52 - Call of Meetings by Trustee.
Page 53 - provided
Page 54 - Supplemental Indentures without Consent of Holders.
Page 55 - Supplemental Indentures with Consent of Holders.
Page 56 - Effect of Supplemental Indentures.
Page 57 - Company May Consolidate, Etc. on Certain Terms.
Page 58 - Evidence to Be Given to Trustee
Page 59 - N/A
Page 60 - N/A
Page 61 - Conversion Procedure; Settlement Upon Conversion.
Page 62 - Notice of Conversion
Page 63 - provided
Page 64 - provided
Page 65 - Additional Shares
Page 66 - provided
Page 67 - Adjustment of Conversion Rate.
Page 68 - divided by
Page 69 - Distributed Property
Page 70 - Spin-Off
Page 71 - Spin-Off Valuation Period
Page 72 - Expiration Date
Page 73 - Tender/Exchange Offer Valuation Period
Page 74 - N/A
Page 75 - N/A
Page 76 - Adjustments of Prices.
Page 77 - Effect of Recapitalizations, Reclassifications and Changes of the Common Stock.
Page 78 - multiplied by
Page 79 - Responsibility of Trustee.
Page 80 - Stockholder Rights Plans.
Page 81 - Fundamental Change Repurchase Notice
Page 82 - provided
Page 83 - Withdrawal of Fundamental Change Repurchase Notice.
Page 84 - Covenant to Comply with Applicable Laws Upon Repurchase of Notes
Page 85 - Redemption Price
Page 86 - N/A
Page 87 - Effect of Notice of Optional Redemption.
Page 88 - Provisions Binding on Company s Successors.
Page 89 - provided
Page 90 - Evidence of Compliance with Conditions Precedent; Certificates and Opinions of Counsel to Trustee.
Page 91 - Authenticating Agent.
Page 92 - Execution in Counterparts.
Page 93 - USA PATRIOT Act.
Page 94 - Signature Page to Indenture
Page 95 - EXHIBIT A
Page 96 - Company
Page 97 - This Note, and any claim, controversy or dispute arising under or related to this Note, shall be con
Page 98 - Remainder of Page Intentionally Left Blank
Page 99 - N/A
Page 100 - N/A
Page 101 - Notes
Page 102 - N/A
Page 103 - SCHEDULE A
Page 104 - ATTACHMENT 1
Page 105 - N/A
Page 106 - ATTACHMENT 2
Page 107 - ATTACHMENT 3
Page 108 - Dated: Signature(s) Signature Guarantee Signature(s) must be guaranteed by an eligible Guarantor Ins
Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com